Compare VYX & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VYX | EVO |
|---|---|---|
| Founded | 1881 | 1993 |
| Country | United States | Germany |
| Employees | 13500 | 4553 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 980.9M | 1.1B |
| IPO Year | N/A | N/A |
| Metric | VYX | EVO |
|---|---|---|
| Price | $7.22 | $3.06 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | ★ $13.67 | $7.00 |
| AVG Volume (30 Days) | ★ 2.2M | 47.1K |
| Earning Date | 05-07-2026 | 04-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1.37 |
| Revenue Next Year | N/A | $10.05 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.02 | $2.31 |
| 52 Week High | $14.67 | $4.42 |
| Indicator | VYX | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 55.89 | 56.03 |
| Support Level | $6.10 | $2.88 |
| Resistance Level | $7.26 | $3.75 |
| Average True Range (ATR) | 0.40 | 0.07 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 48.80 | 89.58 |
NCR Voyix Corp is a company providing services of digital commerce solutions for retail, restaurant, and digital banking. The company operates in two reportable segments: Retail, and Restaurants. The Retail segment provides software solutions for retailers of all sizes, enhancing operational efficiency and customer experience. The Restaurants segment offers end-to-end technology solutions for food service establishments, improving operational efficiency, and customer satisfaction, and reducing costs. The company derives maximum revenue from Retail segment. Geographically, the company operates in United States, Americas (excluding United States), Europe, Middle East and Africa, and Asia Pacific. It derives maximum revenue from United States.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.